Dorsey Wright & Associates Acquires New Position in Abivax SA Sponsored ADR $ABVX

Dorsey Wright & Associates bought a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the fourth quarter, according to its most recent filing with the SEC. The firm bought 16,620 shares of the company’s stock, valued at approximately $2,241,000.

Several other large investors also recently bought and sold shares of the stock. Bank of America Corp DE raised its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after buying an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after buying an additional 2,595 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Abivax by 6.0% during the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after buying an additional 56,235 shares during the last quarter. Woodline Partners LP increased its position in shares of Abivax by 319.5% in the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock valued at $1,262,000 after acquiring an additional 153,788 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of Abivax in the 2nd quarter valued at $139,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Analyst Ratings Changes

ABVX has been the subject of a number of research reports. Barclays lifted their price target on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Oddo Bhf reissued an “outperform” rating on shares of Abivax in a report on Thursday, April 9th. Jefferies Financial Group cut Abivax from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $160.00 to $90.00 in a research note on Tuesday, June 2nd. Citizens Jmp lifted their target price on Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 2nd. Finally, Morgan Stanley decreased their target price on Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a report on Tuesday, June 2nd. Twelve investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $130.08.

Abivax Trading Down 1.0%

Abivax stock opened at $99.15 on Friday. The stock’s 50 day simple moving average is $114.46 and its two-hundred day simple moving average is $118.30. Abivax SA Sponsored ADR has a 12 month low of $5.69 and a 12 month high of $148.83. The firm has a market cap of $7.91 billion, a PE ratio of -19.03 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The firm had revenue of $1.56 million during the quarter, compared to analysts’ expectations of $0.40 million. On average, equities research analysts forecast that Abivax SA Sponsored ADR will post -3.4 EPS for the current year.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.